+ HEALTH Rationale and objectives To propose a new imaging biomarker, the pulmonary artery-to-vein volume difference (…± HEALTH Rationale and objectives The international application of artificial intelligence (AI) for lesion detection b…± HEALTH Rationale and objectives To address the challenge of preoperative prediction of synchronous liver metastasis…± HEALTH Objectives To conduct a nationwide survey among professionals working in oncology departments in China to inv…+ HEALTH The utilization of deep convolutional neural networks for the purpose of diagnosing diseases in the skin area…± HEALTH BACKGROUND . Gadolinium-based contrast agents remain essential for MRI but carry risks. Deep learning (DL) me…+ SCIENCE Gas Chromatography is a versatile separation technique widely used in analytical chemistry for constituent de…+ HEALTH Background Intracardiac echocardiography (ICE) facilitates left atrial (LA) reconstruction during atrial fibr…
TruaceTracing the truth around AIThursday, August 27, 2026
Subscribe
TRV-2026-0909Certified recordPeer-reviewed

Pulmonary Artery-to-Vein Volume Difference: A New Imaging Biomarker for Risk Stratification in Acute Pulmonary Embolism

Rationale and objectives To propose a new imaging biomarker, the pulmonary artery-to-vein volume difference (PAVVD), and evaluate its efficacy in risk stratification of acute pulmonary embolism (APE) compared with traditional computed tomography pulmonary angiography (CTPA) parameters, as well as the impact of chronic pulmonary disease (CPD). Materials and methods This retrospective study included 134 patients with APE (high/intermediate-high risk, n = 46; intermediate-low/low risk, n = 88) from April 2023 to Ma…

Health · G Space — documented gain · certified 2026-08-27 · v1 · article view · machine-readable

Current reading — gain

Automated AI quantification of pulmonary artery-to-vein volume difference achieved the highest discrimination for high/intermediate-high risk acute pulmonary embolism with low missed-diagnosis risk.

What this doesn’t fix

Retrospective single-cohort design with 134 patients limits generalizability and requires external validation.

Evidence

Reader signal

How should this claim be treated?

Cite this record

Truvace Impact Record TRV-2026-0909, v1: “Pulmonary Artery-to-Vein Volume Difference: A New Imaging Biomarker for Risk Stratification in Acute Pulmonary Embolism.” Truvace, 2026-08-27. /record/TRV-2026-0909 (accessed at citation time). sha256 9584d4b2b246203c…

Calibration history

Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.

  1. Certifiedv19584d4b2b246…

    Certified into the record

Verify this record
How to verify without trusting this page

Fetch the canonical text of any version from /api/record/TRV-2026-0909 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.